FINHUB Insights

BMY · Q1 FY25 · Jan 1 – Mar 31, 2025

Bristol Myers Squibb Q1 FY25: where the revenue came from and where it went

Bristol Myers Squibb Q1 FY25: revenue $11.2B (−6% year over year). Net profit $2.5B. Largest cohort Eliquis $3.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 1 – Mar 31, 2025
Reported
Apr 24, 2025 10-Q
Sankey diagram of Bristol Myers Squibb's income statement for Q1 FY25: revenue of $11.2 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$11.2B −6% year over year
Gross profit$8.2B 73% margin
Operating profit$-0.5B -5% margin
Net profit$2.5B 22% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
ItemValueShare of revenueYear over year
Revenue 11.2 100% −6%
Eliquis 3.6 32%
Opdivo 2.3 21%
Other 1.8 16%
Revlimid 0.9 8%
Orencia 0.8 7%
Pomalyst/Imnovid 0.7 6%
Yervoy 0.6 5%
Reblozyl 0.5 4%
Cost of revenue−327%
Gross profit8.273% margin−2pp
Research & development−2.320%−3pp
SG&A−1.614%−6pp
Other−4.843%+0pp
Operating profit-0.5-5% margin+0pp
Tax−0.5
Net profit2.522%+122pp
Filing on EDGAR More quarters of BMY

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters